<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PREGABALIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PREGABALIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Peripheral and central neuropathic pain</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 150 mg daily in 2&#8211;3 divided doses, then increased if necessary to 300 mg daily in 2&#8211;3 divided doses, dose to be increased after 3&#8211;7 days, then increased if necessary up to 600 mg daily in 2&#8211;3 divided doses, dose to be increased after 7 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive therapy for focal seizures with or without secondary generalisation</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg twice daily, then increased in steps of 50 mg daily, dose to be increased at 7 day intervals, increased to 300 mg daily in 2&#8211;3 divided doses for 7 days, then increased if necessary up to 600 mg daily in 2&#8211;3 divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Generalised anxiety disorder</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 150 mg daily in 2&#8211;3 divided doses, then increased in steps of 150 mg daily if required, dose to be increased at 7 day intervals, increased if necessary up to 600 mg daily in 2&#8211;3 divided doses.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>





      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Initially 75&#8239;mg daily and maximum 300&#8239;mg daily if eGFR 30&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>Initially 25&#8211;50&#8239;mg daily and maximum 150&#8239;mg daily in 1&#8211;2 divided doses if eGFR 15&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>Initially 25&#8239;mg once daily and maximum 75&#8239;mg once daily if eGFR less than 15&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Appetite changes, blurred vision, confusion, constipation, diplopia, disturbances in muscle control and movement, dizziness, drowsiness, dry mouth, euphoria, flatulence, impaired attention, impaired memory, insomnia, irritability, malaise, oedema, paraesthesia, sexual dysfunction, speech disorder, visual disturbances, visual field defects, vomiting, weight gain,
              </p>
              <p>
                <strong>uncommon:</strong> Abdominal distension, abnormal dreams, agitation, arthralgia, chills, cognitive impairment, depersonalisation, depression, dry eye, dyspnoea, dysuria, first-degree AV block, flushing, gastro-oesophageal reflux disease, hallucinations, hyperacusis, hypersalivation, hypertension, hypoglycaemia, hypotension, hypotension, lacrimation, myalgia, nasal dryness, nasopharyngitis, panic attacks, rash, stupor, sweating, syncope, tachycardia, taste disturbance, thirst, thrombocytopenia, urinary incontinence,
              </p>
              <p>
                <strong>rare:</strong> Arrhythmia, ascites, bradycardia, breast discharge, breast hypertrophy, breast pain, cold extremities, cough, dysphagia, epistaxis, hyperglycaemia, hypokalaemia, leucopenia, menstrual disturbances, neutropenia, oliguria, pancreatitis, parosmia, renal failure, rhabdomyolysis, rhinitis, urticaria, weight loss,
              </p>
              <p>
                <strong>notKnown:</strong> Aggression, congestive heart failure, convulsions, diarrhoea, encephalopathy, headache, keratitis, nausea, pruritus, QT-interval prolongation, Stevens-Johnson syndrome, suicidal ideation, urinary retention,
              </p>
        
        
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Conditions that may precipitate encephalopathy
          </li>
          <li>
            severe congestive heart failure
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Pregabalin doses in BNF may differ from those in product literature.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Flavours of oral liquid formulations may include strawberry.</p>
            </section>
      </section>

      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Avoid abrupt withdrawal (taper over at least 1 week).</p>
            </section>
      </section>








      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PREGABALIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,
            powder,

            <div id="PHP76407"><a href="../medicinalForm/PHP76407.html" data-target="#PHP76407" data-action="load">Capsule</a></div>
            <div id="PHP76434"><a href="../medicinalForm/PHP76434.html" data-target="#PHP76434" data-action="load">Oral solution</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
